How Does Modern-Day Compounding Create Uncertainty, Inconsistency & Risk to Patients?

Episode 144

0:00-26:48

In this episode of Derms and Conditions, host James Q. Del Rosso, DO is joined by Stefan Weiss, MD for a focused discussion on compounding in dermatology, an area that often operates with less visibility but carries important clinical implications. The conversation centers on the regulatory and practical differences between 503A and 503B compounding pharmacies, with particular attention to 503A facilities, where customized medications are prepared based on individual prescriptions. They outline key concerns with this model, including variability in formulation, lack of standardized testing, and limited oversight compared with FDA-approved therapies. Unlike commercially developed medications, compounded products are not required to undergo stability testing, penetration studies, or clinical trials, raising questions about consistency, efficacy, and safety. A recurring theme is the challenge of knowing exactly what patients receive. Without controls on formulation integrity or bioavailability, clinicians may encounter variability not only between pharmacies, but even between batches from the same source, highlighting how this uncertainty can complicate treatment decisions. The episode also contrasts compounded therapies with FDA-approved options, using topical clascoterone as an example of a rigorously tested, standardized formulation.

Publisher

Derms and Conditions

Published

April 30, 2026

Duration

27 min

Format

Podcast

Category

Lifestyle · Medicine

Source

RSS feed

Host

Dermsquared

DA

Derms and Conditions

@dermsandconditions

#compoundingcreateuncertainty #inconsistency #patients #medicine

The Nile